3-Ethyl-1-phenyl-2-(1H) pyridone | 182681-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Ethyl-1-phenyl-2-(1H) pyridone
• 英文别名: 3-Ethyl-1-phenylpyridin-2-one
• CAS: 182681-80-7
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: GQDKHRWJZICYCI-UHFFFAOYSA-N

物化性质

• 沸点：
  344.2±15.0 °C(Predicted)
• 密度：
  1.104±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
  申请人：BLATT LAWRENCE M.

  公开号：US20090286843A1

  公开（公告）日：2009-11-19

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合物在内的组合物。该实施例还提供了治疗方法，包括治疗黄热病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述化合物或组合物的有效量。
• Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone
  申请人：Margolin Solomon B.

  公开号：US20110092549A1

  公开（公告）日：2011-04-21

  A pharmaceutical composition comprising 5-ethyl-1-phenyl-2-(1H)-pyridone (5-EPP) and its use for the treatment of sepsis are disclosed.

  本发明揭示了一种含有5-乙基-1-苯基-2-(1H)-吡啶酮（5-EPP）的制药组合物，并其用于治疗败血症的用途。
• Aerosol pirfenidone and pyridone analog compounds and uses thereof
  申请人：Avalyn Pharma Inc.

  公开号：US10028966B2

  公开（公告）日：2018-07-24

  Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

  本文公开了用于气雾化的吡非尼酮或吡啶酮类似物化合物制剂，以及使用此类制剂气雾给药吡非尼酮或吡啶酮类似物化合物以预防或治疗各种纤维化和炎症性疾病，包括与肺、心、肾、肝、眼和中枢神经系统有关的疾病。在某些实施方案中，本文所述的吡非尼酮或吡啶酮类似化合物制剂和给药方案可实现吡非尼酮或吡啶酮类似化合物的有效局部给药。组合物包括本文所述的所有制剂、试剂盒和装置组合。方法包括用于生产和使用所述组合物的吸入程序、适应症和生产工艺。
• Pyrrolotriazine compounds as TAM inhibitors
  申请人：Incyte Corporation

  公开号：US10442810B2

  公开（公告）日：2019-10-15

  This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

  本申请涉及式 I 的化合物： 或其药学上可接受的盐类，它们是 TAM 激酶的抑制剂，可用于治疗癌症等疾病。